ONdrugDelivery - ONdrugDelivery - drug delivery industry specialised b2b information

INTERVIEW

A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors

In this exclusive interview Portal Instruments CEO Patrick Anquetil offers insight into the extensive waste involved in the self-injection market. He explains how pivoting from a model focused on fully disposable devices to reusable electromechanical autoinjectors could offer a more sustainable and cost-effective path forward.

SUSTAINABILITY IN DRUG DELIVERY: INNOVATIONS IN PLASTIC COMPONENTS AND CIRCULAR DESIGN

Edwin van der Heul considers the increasing regulatory pressure on manufacturers to deliver sustainable solutions in the medical device industry. This article explores these innovations and their impact on the future of drug delivery devices.

The Transition to Lower-Global-Warming-Potential Propellants in pMDIs

Aptar Pharma’s Chris Baron discusses how the company has developed a new metering valve technology platform – ZEN30 Futurity™ – that is compatible with leading lower-GWP propellants. By collaborating with drug developers, regulators and the pMDI supply chain, Aptar Pharma aims to support the reduction of the CO₂ footprint of pMDIs while ensuring that the pharmaceutical industry’s strict regulatory requirements are met or exceeded.

FIVE CRUCIAL COMPONENTS OF A SUCCESSFUL SUSTAINABLE PROCUREMENT STRATEGY

PCI Pharma Services

FIVE CRUCIAL COMPONENTS OF A SUCCESSFUL SUSTAINABLE PROCUREMENT STRATEGY

Ann Cartwright and Tim Hansen explain the five key components of PCI's sustainable procurement strategy to increase efficiency, meet regulatory demands and support business resilience and sustainability in the long term.

UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS

Stevanato Group

UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS

Stevanato Group examines how semi-reusable, modular designs like its Vertiva 10 mL on-body delivery system can reconcile patient demands for ease of use with growing expectations for sustainability, sharing new UK preference data and lifecycle analysis that reveal significant waste and emissions reductions.

SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND

SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND

Lorenzo Biasio and Gloria Skibba discuss the integration of Ypsomed’s Net Zero Program into its self-injection platforms. With the evolution of GLP-1 therapies and the exploration of higher-dose formulations, the demand for higher-volume autoinjectors is increasing; this article explains how Ypsomed has also applied its sustainability principles to larger-volume delivery.

THE PFAS PROBLEM: IMPROVING SUSTAINABILITY WITH NONWOVEN INNOVATION

THE PFAS PROBLEM: IMPROVING SUSTAINABILITY WITH NONWOVEN INNOVATION

Jack Eaton considers the current landscape for drug delivery and packaging, and how developments and research in nonwoven and fibrous materials can help businesses address the problem of per- and polyfluoroalkyl substances.

AI, DATA AND PARTNERSHIPS: THE BUILDING BLOCKS FOR MORE SUSTAINABLE CLINICAL TRIALS

AI, DATA AND PARTNERSHIPS: THE BUILDING BLOCKS FOR MORE SUSTAINABLE CLINICAL TRIALS

Sas Maheswaran discusses how artificial intelligence, data and strategic partnerships can make clinical trials more sustainable – both financially and environmentally.

BIOPLASTICS IN DRUG DELIVERY: GETTING RID OF CRITICAL SUBSTANCES AND CARBON EMISSIONS

BIOPLASTICS IN DRUG DELIVERY: GETTING RID OF CRITICAL SUBSTANCES AND CARBON EMISSIONS

Julian Lotz introduces bio-based solutions for drug delivery devices, excelling in quality while meeting upcoming sustainability regulations, and explores the future of bioplastics in the healthcare sector.

IMPORTANCE OF PRE-COLOURED ABS IN INHALATION MEDICAL DEVICES

IMPORTANCE OF PRE-COLOURED ABS IN INHALATION MEDICAL DEVICES

Luca Chiochia discusses the vital role of coloured plastics in medical devices and how the use of pre-coloured, pre-tested solutions can provide not only a significantly reduced regulatory burden for device developers and manufacturers but also a higher quality end product, going on to explain how the company is approaching the critical subject of producing more sustainable polymers.

THE POWER OF PULMONARY: ADVANCES IN INHALED DRUG DELIVERY EXPAND RESPIRATORY TREATMENT OPTIONS

Jonathan Mulpas

THE POWER OF PULMONARY: ADVANCES IN INHALED DRUG DELIVERY EXPAND RESPIRATORY TREATMENT OPTIONS

Jonathan Mulpas discusses how advanced inhaled drug delivery devices, such as dry powder inhalers and non-propellant liquid inhalers, can meet currently unmet needs in the inhalation space, focusing on devices that Aptar and its partners are developing to realise this potential and the expertise that Aptar can offer in this area.

BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS

Dr Heather Jameson

BLISTERS, BONDS AND BIOLOGICS: HOW TO ACHIEVE STABILITY OF DRY POWDER BIOLOGICS

Heather Jameson and Dave Farrow cover the challenging formulation science required to develop a viable dry powder aerosol and examine the inhaler device requirements necessary to protect the formulation throughout its shelf life while also ensuring consistent, high-performance delivery.

SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?

Kamaal de Silva

SHIELDED THERAPEUTICS: COULD POLYMERIC NANOPARTICLES SAFEGUARD A NEW GENERATION OF INHALED DRUGS?

Kamaal de Silva and Ethan Miller provide an overview of the benefits of polymeric nanoparticles in pulmonary drug delivery and their potential to overcome key challenges in respiratory medicine, while summarising the range of pulmonary delivery devices that could benefit from their use.

DEVELOPING ROBUST ORALLY INHALED PRODUCTS TO ACHIEVE BETTER PATIENT OUTCOMES

Dr Clair Brooks

Copley Scientific

DEVELOPING ROBUST ORALLY INHALED PRODUCTS TO ACHIEVE BETTER PATIENT OUTCOMES

Clair Brooks looks at some of the in-use issues and patient effects that good design of devices for orally inhaled drug products can address within the context of regulatory requirements for the demonstration of robustness.

MANUFACTURE OF MOISTURE-SENSITIVE POWDERS FOR INHALATION

Catalent Pharma Solutions

MANUFACTURE OF MOISTURE-SENSITIVE POWDERS FOR INHALATION

Alan Watts, Yusuf Ahmed and Gabriela Dujovny discuss manufacturing methods for inhalation powders and explain how moisture protection is an essential consideration throughout the manufacturing process.

TRANSFORMING MENTAL HEALTHCARE: THE RISE OF INHALABLE PSYCHEDELICS?

Dr Philippe Rogueda

TRANSFORMING MENTAL HEALTHCARE: THE RISE OF INHALABLE PSYCHEDELICS?

Philippe Rogueda discusses how inhaled psychedelic therapies are emerging as a potential game-changer in mental health due to their fast onset and precise dosing, and how their potential has resulted in a growing pipeline of therapies, paving the way for a new era in mental healthcare.

NOSE-TO-BRAIN DELIVERY: PATIENT-CENTRIC DEVICE DEVELOPMENT AND PERFORMANCE TESTING

NOSE-TO-BRAIN DELIVERY: PATIENT-CENTRIC DEVICE DEVELOPMENT AND PERFORMANCE TESTING

Sophie Conte and Alain Regard, describe Nemera’s journey in nose-to-brain device development, highlighting the evaluation tools, methods and usability testing developed in-house to steer innovative device design and engineering.

MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING

MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING

Eric Kaneps discusses key emerging drug delivery trends poised to help the pharmaceutical industry meet the growing demand for patient-centric solutions, with a particular focus on nasal drug delivery, as the nasal spray repositioning of existing drugs offers a range of benefits, including rapid onset of action, improved bioavailability and ease of administration for patients.

REALISTIC BREATHING PROFILES IN IN SILICO MODELS: A PARTNERSHIP APPROACH

Dr Carolina Dantas

Pulmotree Medical

REALISTIC BREATHING PROFILES IN IN SILICO MODELS: A PARTNERSHIP APPROACH

Carolina Dantas, Ulf Krueger and Howard Burnett discuss the critical need for precision when delivering biologics to the lungs, how PULMOTREE’s Kolibri is able to achieve this using guided breathing, and how the use of realistic breathing profiles can improve outcomes and decrease risk with in vitro and in silico testing.

CONFERENCE PREVIEW: SMI.LONDON

CONFERENCE SHOWCASE

CONFERENCE PREVIEW: SMI.LONDON

Join colleagues from across the inhalation space at SMI.London 2025, the only conference dedicated to soft mist inhalers (SMIs) worldwide. The event will take place on Wednesday, June 25, 2025, at the Pullman London St Pancras, hosted by Merxin.

A COMPREHENSIVE APPROACH TO ADDRESSING UNMET NEEDS IN INTRAVITREAL INJECTIONS

Dr Reza Abedian

A COMPREHENSIVE APPROACH TO ADDRESSING UNMET NEEDS IN INTRAVITREAL INJECTIONS

Dr Reza Abedian, Marie Stockton and Bernd Zeiss consider the complexities and clinical unmet needs of intravitreal injections and discuss how Gerresheimer’s syringe technology can help overcome these challenges.

GLAUCOMA IN VIEW: IMPROVING PATIENT ADHERENCE WITH MULTIDOSE EYEDROPPERS FOR PRESERVATIVE-FREE SOLUTIONS

GLAUCOMA IN VIEW: IMPROVING PATIENT ADHERENCE WITH MULTIDOSE EYEDROPPERS FOR PRESERVATIVE-FREE SOLUTIONS

Zoë Davidson considers the impact of glaucoma on global health and the challenges presented by the increasing prevalence of this disease in the ageing global population, discussing how Novelia®, Nemera’s multidose eyedropper for preservative-free formulations, is well-positioned to address many of the challenges presented by glaucoma treatments, from ease of use to sustainability.

GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES

GENE THERAPY IN OPHTHALMOLOGY: ADVANCES AND CHALLENGES

Joe Batley and Lorna Barron provide an overview of the latest cutting-edge ophthalmic delivery methods and discuss possible future developments.

A NEW DELIVERY PLATFORM FOR SUPRACHOROIDAL ADMINISTRATION USING WEST’S ADVANCEABLE MICRONEEDLE DEVICE

Dr Anu Prabhathachandran

West Pharmaceutical Services

A NEW DELIVERY PLATFORM FOR SUPRACHOROIDAL ADMINISTRATION USING WEST’S ADVANCEABLE MICRONEEDLE DEVICE

Anu Prabhathachandran, Menachem Peretz and Manali Potnis discuss the growing need for more effective delivery of ophthalmic therapeutics to meet the needs of the ageing population, including how delivery into the suprachoroidal space may present an appealing alternative to intravitreal injection. They introduce West Pharmaceutical Service’ Suprachoroidal Advanceable Microneedle Device, which offers several advantages for overcoming the challenges with suprachoroidal space.

REVOLUTIONISING EYE CARE: THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES

REVOLUTIONISING EYE CARE: THE POTENTIAL OF ANTISENSE OLIGONUCLEOTIDES

Binbin Tian discusses antisense oligonucleotides and considers their potential as treatments for genetic and multifactorial ophthalmic diseases previously considered untreatable. The article considers how these therapies function as treatments, their current state of development, challenges in their delivery and the evolving regulatory landscape

INTRODUCING THE TERUMO INJECTION FILTER NEEDLE – A FIRST STEP OF THE INFINO™ DEVELOPMENT PROGRAMME

Terumo Medical Care Solutions

INTRODUCING THE TERUMO INJECTION FILTER NEEDLE – A FIRST STEP OF THE INFINO™ DEVELOPMENT PROGRAMME

Thomas Isaac considers the issues associated with injection to highly sensitive areas, such as the vitreous body, and the potential to optimise needle design and features to address these issues, discussing the key features of Terumo’s Injection Filter Needle, indicated for hypodermic and intravitreal injections within this context.

THE RISE OF LARGE-VOLUME SUBCUTANEOUS ADMINISTRATION OF BIOPHARMACEUTICALS, AND DELIVERY IMPLICATIONS

Dr Andreas Schneider

THE RISE OF LARGE-VOLUME SUBCUTANEOUS ADMINISTRATION OF BIOPHARMACEUTICALS, AND DELIVERY IMPLICATIONS

Andreas Schneider and Jakob Lange consider the SC administration of larger volumes of biopharmaceuticals in the pharma industry and summarise a recent study that reviews clinical-stage and approved IV and SC biopharmaceuticals to provide valuable guidance for new product development, as well as for marketing and commercialisation strategies in the rapidly evolving large-volume SC landscape.

1
2
3
…
64
Next

See what ondrugdelivery's readers and contributors think

Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.

Top